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Introduction 
RNA molecules contain a number of modified nucleosides that are introduced post-transcriptionally. More than 
100 species of RNA modifications are reported so far. Especially, 70% of them are found in tRNAs. tRNA 
modifications have been well-studied for more than half century, and are required for tRNA stability, accurate 
decoding, efficient aminoacylation, and so on. 
N6-threonylcarbamoyladenosine (t6A) is an evolutionally conserved modification found in tRNAs which 
decode A-starting codons (ANN). t6A is a modified adenosine conjugated with threonine through carbonyl group 
at N6 position of adenine base. t6A is present at the position 3’-adjacent to the anticodon (position 37). t6A37 
prevents base-paring between t6A37 and U33 to stabilize the anticodon loop structure. This modification is 
required for various steps in translation including aminoacylation, tRNA binding to the A-site codon, efficient 
translocation, reading frame maintenance and so on. 
In human mitochondria, t6A is present at position 37 of five species of mt-tRNAs. On the basis of 
functional importance of this modification in most organisms, I aim to characterize biogenesis and function of 
t6A in human mt-tRNAs, and investigate pathogenic mutations in mt-tRNAs that impair t6A formation. 
 
Subcellular localization of YRDC and OSGEPL1 
YRDC and OSGEPL1 were predicted to be tRNA-modifying enzymes for t6A37 formation in human mt-tRNAs, 
but no direct evidence had been provided. Transient expression of YRDC and OSGEPL1 with FLAG-tag in 
HeLa cells was performed, and the proteins were immunoprecipitated from the cell lysates. Mass spectrometric 
analyses revealed that N-termini of both proteins are truncated, indicating that mitochondria targeting sequences 
(MTS) of both proteins are cleaved after importation to mitochondria. Immunostaining revealed that OSGEPL1 
was clearly localized in mitochondria. In contrast, YRDC predominantly localizes to cytoplasm. However, I 
detected small fraction of YRDC in mitochondrial fraction by western blotting. YRDC has a weak MTS, because 
a large fraction of YRDC localized in cytoplasm participates in t6A37 formation in cytoplasmic tRNAs. 
 
Loss of OSGEPL1 causes mitochondrial dysfunction 
To demonstrate that OSGEPL1 is responsible for t6A37 formation in mt-tRNAs, I knocked out OSGEPL1 in 
HEK293T cells using the CRISPR/Cas9 system, and obtained two knockout (KO) cell lines in which both alleles 
have frameshift mutations. Lack of OSGEPL1 protein in the KO cell was confirmed by western blotting. Then, I 
isolated t6A37-bearing mt-tRNAs from OSGEPL1 KO cells. Mass spec analyses (RNA-MS) revealed no t6A37 
in these tRNAs. Next, I examined mitochondrial activity of OSGEPL1 KO cells. These KO cells grew well in 
glucose medium, but did not grow in galactose medium efficiently, indicating that OSGEPL1 KO cells have little 
mitochondrial activity. I conducted pulse labelling experiment to estimate rate of mitochondrial translation. 
Compared to WT cells, severe reduction of mitochondrial protein synthesis was observed in the KO cells. 
Steady-state levels of mitochondrial protein subunits of respiratory chain complexes including ND2, ND5 and 
COI were markedly reduced in mitochondria, showing that lack of t6A37 in mt-tRNAs impairs mitochondrial 
protein synthesis. I also observed little oxygen consumption, reduced complex I activity, and low ATP 
production in OSGEPL1 KO cells. Taken together, t6A37 in mt-tRNAs is required for efficient translation and 
respiratory activity of mitochondria. 
 
In vitro reconstitution of t6A37 and kinetic measurement 
I obtained recombinant YRDC and OSGEPL1 and examined in vitro reconstitution of t6A37 on mt-tRNAs. As 
expected, YRDC and OSGEPL1 successfully introduced t6A37 in all five species of mt-tRNAs in the presence of 
L-threonine, bicarbonate, and ATP as substrates. Next I measured the kinetic parameters for mitochondrial t6A37 
formation on mt-tRNAThr, and determined apparent Km values for each substrate. The Km value for mt-tRNAThr 
was sub-micromolar, indicating that OSGEPL1 had sufficient affinity for the tRNA substrate. By contrast, the 
Km value for bicarbonate was quite high, but within the range of bicarbonate concentration (10–40 mM) in 
human mitochondria, indicating that mitochondrial t6A37 formation could be regulated by cellular bicarbonate or 
CO2 concentration. I also found high Km value for TC-AMP formation catalyzed by YRDC, demonstrating that 
mitochondrial TC-AMP formation also requires a high cellular concentration of CO2/bicarbonate. 
 
Pathogenic mutations impair mitochondrial t6A37 formation 
Pathogenic mutations in mtDNA are associated with mitochondrial disorders. Given that t6A37 plays critical 
roles in mitochondrial translation, I speculated that some pathogenic point mutations in mt-tRNA genes impair 
t6A37 formation, in turn leading to mitochondrial dysfunction. From among the previously described pathogenic 
mutations, I prepared 21 mutant mt-tRNAs for Thr, Lys, and Asn by in vitro transcription, and then examined 
their ability to undergo t6A37 modification mediated by YRDC and OSGEPL1. Collectively, two target-site 
mutations and nine mutations strongly affected t6A37 formation, indicating that loss of t6A37 is a major cause of 
mitochondrial disorders. Multiple mutations that reduced t6A37 reside in the anticodon arm of mt-tRNAs, 
suggesting that OSGEPL1 primarily recognizes the anticodon stem-loop structure to introduce t6A37. 
 
Hypomodification of t6A37 in mt-tRNA in patient cells 
To verify the loss of t6A37 in mutant mt-tRNAs in patient cells, I obtained fibroblasts and myoblasts harboring 
the A15923G mutation from a 12-year-old female patient with symptoms of myoclonic epilepsy with ragged-red 
fibers (MERRF), lactic acidosis, short stature, and hearing loss. I isolated mt-tRNAThr from the patient’s cells 
and analyzed their modification status by RNA-MS. I observed low levels of t6A37 in the mutant tRNAs isolated 
from myoblasts and fibroblasts. This finding is consistent with our in vitro mutation studies, and demonstrates 
that pathogenic point mutations in mtDNA impaired t6A37 formation of mt-tRNA in patient cells, strongly 
indicating that the lack of t6A37 contributes to molecular pathogenesis of mitochondrial disease. 
 
Regulation of mitochondrial t6A37 formation by sensing CO2/bicarbonate 
To determine whether t6A37 frequency is regulated by CO2/bicarbonate concentration, I cultured HEK293T cells 
in a medium without sodium bicarbonate in the absence of 5% CO2 (air) for 6 days. Subsequently, five species of 
mt-tRNAs were isolated and subjected to RNA-MS. The t6A37 frequencies of two mt-tRNAs decreased 
markedly, whereas the frequency decreased slightly in the other three mt-tRNAs; no change was observed in 
cyto-tRNAIle. As expected, when sodium bicarbonate was added back to the medium the t6A37 frequencies of 
the two mt-tRNAs increased gradually as a function of bicarbonate concentration. The different responses of 
t6A37 formation in the five mt-tRNAs to bicarbonate concentration might be due differences in efficiency of 
t6A37 formation. 
Rapidly growing tumors frequently fall into hypoxia due to low oxygen availability. Given that 
mitochondrial CO2/bicarbonate is largely provided by TCA cycle, I asked whether mitochondrial t6A37 could be 
affected by hypoxic conditions in solid tumors. For these experiments, I prepared solid tumor xenografts by 
subdermally injecting colorectal adenocarcinoma HT-29 cells into nude mice, and then isolated two mt-tRNAs 
for RNA-MS. I clearly detected hypomodification of t6A37 in the mt-tRNAs isolated from the tumor, whereas 
both mt-tRNAs isolated from cell culture were fully modified. This finding suggests that t6A37 frequency can be 
modulated by hypoxic conditions in solid tumors. 
 
Conclusions 
In this study, I showed that YRDC and OSGEPL1 are required for t6A37 formation in five mt-tRNAs and that 
t6A37 plays critical roles in protein synthesis and respiratory activities in mitochondria. Kinetic studies revealed 
that mitochondrial t6A37 formation is dynamically regulated by cellular CO2/bicarbonate concentration. In 
support of this finding, I observed hypomodification of t6A37 in two mt-tRNAs isolated from human cells 
cultured with non-bicarbonate medium, as well as hypoxic solid tumors, implying codon-specific regulatory 
translation under hypoxic conditions. I also identified pathogenic point mutations that impaired t6A37 formation 
in mt-tRNAs and confirmed low levels of t6A37 in mt-tRNAThr with the A15923G mutation isolated from a 
patient with MERRF-like symptoms, indicating that the lack of t6A37 has pathological consequences. 
